Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 16, 2026

Tecan presents 2025 results and provides details on program to reignite profitable growth

View original at globenewswire.com
Tecan presents 2025 results and provides details on program to reignite profitable growth Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan presents 2025 results and provides details on program to reignite profitable growth Financial results for the full year 2025 – Summary S…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Tecan expects to return to average organic growth rates in the mid- to high-single-digit percentage range in local currencies from 2029 onwards, while continuously improving profitability

    60% confidence
  • Tecan expects sales to increase in the low single-digit percentage range in local currencies for 2026

    60% confidence
  • Tecan intends to outgrow the market by leading its AI- and data-driven future

    60% confidence
  • Tecan forecasts adjusted EBITDA margin of 15.5% to 16.5% of sales for 2026, including 110 basis points headwind from FX and tariffs

    60% confidence
  • Our 2025 performance does not reflect Tecan's potential. We are acting decisively to change that. Our core is intact, and our balance sheet is strong.

    60% confidence
  • Tecan expects continued gradual improvement in end markets, with market growth increasing to a range of 1% to 3% in the years 2027-2028

    60% confidence
  • During 2025, demand for instruments in Academia & Government was significantly impacted by budget uncertainty and volatile public funding, particularly in the US and China

    60% confidence
  • Technology leadership and the ability to translate it into profitable growth are decisive, for customers and shareholders alike

    60% confidence
  • From 2029 onwards, Tecan assumes a return to normal market conditions, with market growth in the previous range of 3% to 5%

    60% confidence
  • The forces shaping the industry's future - AI integration, automation, scientific complexity, economic pressure - are powerful and durable and will drive significant growth in laboratory automation over the coming decade

    60% confidence
  • For 2026, Tecan expects end markets to recover gradually with market growth ranging from a moderate decline to moderate growth

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com